Trial reportNeurology2013
Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.
Trial report in Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 5 syntheses or guidelines pooled it, 198 citations in OpenAlex.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Rituximab in stiff-person syndrome with glutamic acid decarboxylase 65 autoantibody: a systematic review.Journal of neurology · 2025Pooled it
- Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy: Retrospective Study.Neurology(R) neuroimmunology & neuroinflammation · 2022Pooled it
- Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.The Cochrane database of systematic reviews · 2017Pooled it
- Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.The Cochrane database of systematic reviews · 2016Pooled it
- Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial.Brain : a journal of neurology · 2025Trial
- A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome.Annals of neurology · 2017Trial
- Management and long-term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia-related neuropathy: A single-centre experience.British journal of haematology · 2026Article
- Therapeutic effect of T-cell engager in two patients with autoimmune neuropathy.Nature communications · 2026Article
- Anti-MAG Polyneuropathy: Characterization of the Monoclonal Gammopathy and Clonal B-Cell Population.Journal of immunology research · 2026Article
- Treatment of Anti-myelin-associated Glycoprotein Neuropathy with Tirabrutinib and a 3-year Follow-up.Internal medicine (Tokyo, Japan) · 2025Article
- The changing landscape of primary autoimmune neuropathies.Nature reviews. Neurology · 2025Review
- Frequency and Relevance of MYD88European journal of neurology · 2025Article
- Update on paraproteinemic neuropathy.Current neurology and neuroscience reports · 2025Review
- Article
- Article
- The Role of Complement Activation in IgM M-Protein-Associated Neuropathies.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Rituximab retreatment guided by CD27+ B-cell count vs. clinical relapse in anti-MAG polyneuropathy: a cost-effective approach with lower cumulative doses.Frontiers in neurology · 2025Article
- Monoclonal Gammopathy-Associated Neuropathy.Current hematologic malignancy reports · 2024Review
- Neurological manifestations of MGUS.Hematology. American Society of Hematology. Education Program · 2024Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine whether rituximab 375 mg/m(2) was efficacious in patients with immunoglobulin M (IgM) anti-myelin-associated glycoprotein antibody demyelinating neuropathy (IgM anti-MAG demyelinating neuropathy).
methodsFifty-four patients with IgM anti-MAG demyelinating neuropathy were enrolled in this randomized, double-blind, placebo-controlled trial. The inclusion criteria were inflammatory neuropathy cause and treatment (INCAT) sensory score (ISS) ≥4 and visual analog pain scale >4 or ataxia score ≥2. The primary outcome was mean change in ISS at 12 months.
resultsTwenty-six patients were randomized to a group receiving 4 weekly infusions of 375 mg/m(2) rituximab, and 28 patients to placebo. Intention-to-treat analysis, with imputation of missing ISS values by the last observation carried forward method, showed a lack of mean change in ISS at 12 months, 1.0 ± 2.7 in the rituximab group, and 1.0 ± 2.8 in the placebo group. However, changes were observed, in per protocol analysis at 12 months, for the number of patients with an improvement of at least 2 points in the INCAT disability scale (p = 0.027), the self-evaluation scale (p = 0.016), and 2 subscores of the Short Form-36 questionnaire.
conclusionsAlthough primary outcome measures provide no evidence to support the use of rituximab in IgM anti-MAG demyelinating neuropathy, there were improvements in several secondary outcomes in per protocol analysis. LEVEL OF EVIDENCE: This study provides Class I evidence that rituximab is ineffective in improving ISS in patients with IgM anti-MAG demyelinating neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.